IN THIS ISSUE
Translational and Early Phase Strategies for Treatment
Development: Report of ISCTM Autumn 2013 Symposium
by by Jared W. Young, PhD; William Z. Potter, MD, PhD;
Steve Riley, PharmD, PhD; Geert J. Groeneveld, MD, PhD;
Bruce J. Kinon, MD; Mike F. Egan, MD;
and Douglas E. Feltner, MD
Lessons Learned and Potentials for Improvement in CNS
Drug Development: ISCTM Section on Designing the Right
Series of Experiments
by Steven T. Szabo, MD, PhD; Bruce J. Kinon, MD;
Stephen K. Brannan, MD; Andrew K. Krystal, MD, MSc;
Joop M. A. van Gerven, MD, PhD; Atul Mahableshwarkar, MD;
and Gary S. Sachs, MD
Taking Personalized Medicine Seriously: Biomarker
Approaches in Phase IIb/III Studies in Major Depression
and Schizophrenia
by Harald Murck, MD, PhD; Thomas Laughren, MD;
Femke Lamers, PhD; Rosalind Picard, ScD;
Sebastian Walther, MD; Donald Goff, MD;
and Stephen Sainati, MD, PhD
VOLUME 12 • NUMBER 3–4 MARCH–APRIL 2015 • SUPPLEMENT A
A SUPPLEMENT TO
THE OFFICIAL PUBLICATION OF THE INTERNATIONAL SOCIETY FOR CNS CLINICAL TRIALS AND METHODOLOGY